Prognostic Probability of FDG-PET before Stereotactic Ablative Radiotherapy for Primary Lung Cancer -Review of the Literature - Abstract
Stereotactic Ablative Radiotherapy (SABR) is developing and becoming one of the few curative treatment methods alternative to resection for early-stage lung cancer in inoperable patients. FDG-PET now has many approved indications and is included in guidelines for tumor staging and response assessment. FDG-PET is also used for radiotherapy in lung cancer in many ways (e.g., target delineation, prediction
prognosis); however, there are some limitations, especially motion blur and partial volume effect. Thus prognostic ability of SUVmax is controversial in early-stage lung cancer. We reviewed the utility and limitation of FDG-PET in SABR for early-stage lung cancer.